J Bardfield1, B Agins1, M Palumbo1, A L Wei2, J Morris3, B Marston4. 1. New York State Department of Health AIDS Institute, HEALTHQUAL International, 90 Church Street, 13th Floor, New York, NY 10007, USA. 2. University of California, San Diego School of Medicine, 9500 Gilman Drive, San Diego, CA 92093, USA. 3. Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA. 4. Global AIDS Program, CDC, 1600 Clifton Road, Atlanta, GA 30329, USA.
Abstract
OBJECTIVE: To demonstrate the effectiveness of quality improvement methods to monitor and improve administration of cotrimoxazole (CTX) prophylaxis to improve health outcomes among adults living with HIV/AIDS in low resource countries. DESIGN: Program evaluation. SETTING: HIV/AIDS health care facilities in Uganda, Mozambique, Namibia and Haiti. INTERVENTION: Performance measures based on national guidelines are developed in each country. These may include CD4 monitoring, ART adherence and uptake of CTX prophylaxis. CTX prophylaxis is routinely selected, because it has been shown to reduce HIV-related morbidity and mortality. Patient records are sampled using a standard statistical table to achieve a minimum confidence interval of 90% with a spread of ±8% in participating clinics. If an electronic medical record is available, all patients are reviewed. Routine review of performance measures, usually every 6 months, is conducted to identify gaps in care. Improvement interventions are developed and implemented at health facilities, informed by performance results, and local/national public health priorities. MAIN OUTCOME MEASURE: Median clinic rates of CTX prophylaxis. RESULTS: Median performance rates of CTX prophylaxis generally improved for adult HIV+ patients between 2006 and 2013 across countries, with median clinic rates higher than baseline at follow-up in 16 of 18 groups of clinics implementing CTX -focused improvement projects. CONCLUSIONS: Quality management offers a data-driven method to improve the quality of HIV care in low resource countries. Application of improvement principles has been shown to be effective to increase the rates of CTX prophylaxis in national HIV programs in multiple countries.
OBJECTIVE: To demonstrate the effectiveness of quality improvement methods to monitor and improve administration of cotrimoxazole (CTX) prophylaxis to improve health outcomes among adults living with HIV/AIDS in low resource countries. DESIGN: Program evaluation. SETTING: HIV/AIDS health care facilities in Uganda, Mozambique, Namibia and Haiti. INTERVENTION: Performance measures based on national guidelines are developed in each country. These may include CD4 monitoring, ART adherence and uptake of CTX prophylaxis. CTX prophylaxis is routinely selected, because it has been shown to reduce HIV-related morbidity and mortality. Patient records are sampled using a standard statistical table to achieve a minimum confidence interval of 90% with a spread of ±8% in participating clinics. If an electronic medical record is available, all patients are reviewed. Routine review of performance measures, usually every 6 months, is conducted to identify gaps in care. Improvement interventions are developed and implemented at health facilities, informed by performance results, and local/national public health priorities. MAIN OUTCOME MEASURE: Median clinic rates of CTX prophylaxis. RESULTS: Median performance rates of CTX prophylaxis generally improved for adult HIV+ patients between 2006 and 2013 across countries, with median clinic rates higher than baseline at follow-up in 16 of 18 groups of clinics implementing CTX -focused improvement projects. CONCLUSIONS: Quality management offers a data-driven method to improve the quality of HIV care in low resource countries. Application of improvement principles has been shown to be effective to increase the rates of CTX prophylaxis in national HIV programs in multiple countries.
Authors: Sally Hargreaves; Keiran Rustage; Laura B Nellums; Joshua E Bardfield; Bruce Agins; Pierre Barker; M Rashad Massoud; Nathan P Ford; Meg Doherty; Gillian Dougherty; Satvinder Singh Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: Charles Kiyaga; Vijay Narayan; Ian McConnell; Peter Elyanu; Linda Nabitaka Kisaakye; Eleanor Joseph; Adeodata Kekitiinwa; Jeff Grosz Journal: PLoS One Date: 2021-02-04 Impact factor: 3.240
Authors: Baba M Musa; Everistus Ibekwe; Stanley Mwale; Daniel Eurien; Catherine Oldenburg; Gary Chung; Richard F Heller Journal: F1000Res Date: 2018-06-08